Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

The JD.com announced a quarterly dividend

3/9/23 JD

JD.com reported for 2022

3/9/23 JD

Sberbank's profits will reach pre-crisis levels in 2023

3/9/23 SBER

Voluntary contribution of companies to the budget may also affect Sberbank

3/9/23 SBER

Sberbank will not return a subordinated loan to the treasury

3/9/23 SBER

Safety margin allows Sberbank to pay dividends

3/9/23 SBER

Sberbank reported for 2022 according to IFRS

3/9/23 SBER

VTB intends to sell the sanctions-affected branch in Angola

3/9/23 VTBR

Qualcomm increases quarterly cash dividend by 7%

3/9/23 QCOM

The General Dynamics announced a quarterly dividend

3/8/23 GD